The test developed in the Gastrointestinal Cancer Research Lab at Baylor Research Institute in US examines the levels of a single microRNA - a small RNA molecule that can be readily identified in a wide variety of bodily fluids, including blood.
In the study, the investigators studied several hundred patients with colorectal polyps and cancers and reported that measuring levels of miR-21 in the blood can accurately identify up to 92 per cent of patients with colorectal cancer.
"The development of this biomarker is highly encouraging because high mortality rates associated with colorectal cancer is a consequence of late detection of this disease, underscoring the need for improved early detection, prevention, risk assessment and intervention," said lead author Ajay Goel, director of Epigenetics and Cancer Prevention at Baylor Research Institute.
"This blood-based test could be transformative in how we screen patients for colorectal cancer; it would save lives and could result in major savings of health care dollars," said Michael Ramsay, president of Baylor Research Institute.
The research was published in the Journal of the National Cancer Institute.
